The Claim
In adults with overweight or obesity and cardiovascular disease but without diabetes, once-weekly semaglutide 2.4 mg likely reduces the rate of annual decline in estimated glomerular filtration rate (eGFR) by 0.39 ml/min/1.73m² per year compared to placebo, as determined by a linear random effects model analysis over a median of 182 weeks in a randomized controlled trial involving 17,604 participants.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults who are overweight, have heart disease, but don’t have diabetes, taking a weekly semaglutide shot might help slow down how fast their kidneys lose function each year.
See the scientific wording
In adults with overweight or obesity, cardiovascular disease, and no diabetes, once-weekly semaglutide 2.4 mg likely slows the annual decline in eGFR by 0.39 ml/min/1.73m² per year compared to placebo, based on a linear random effects model analysis over a median of 182 weeks in a randomized controlled trial of 17,604 participants.
What the research says
1 studyStudy: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study tested the same drug, dose, and patient group as the claim and found that semaglutide helped protect kidney function, which supports the idea that it slows kidney decline.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.